Ivermectin (Ivomec)

Ivermectin is the foundational macrocyclic lactone antiparasitic compound that revolutionized veterinary parasitology following its introduction in the early 1980s. Derived from the fermentation products of the soil microorganism Streptomyces avermitilis, ivermectin represented a breakthrough in antiparasitic therapy by offering unprecedented broad-spectrum activity against both internal parasites (nematodes) and external parasites (arthropods) at remarkably low doses. The development of ivermectin earned its discoverers, Satoshi Ōmura and William Campbell, the 2015 Nobel Prize in Physiology or Medicine, recognizing the transformative impact this class of compounds has had on both human and veterinary medicine worldwide. In livestock production, ivermectin has become one of the most widely used antiparasitic agents globally, forming the cornerstone of integrated parasite management programs across diverse production systems.

The mechanism of action of ivermectin involves high-affinity binding to glutamate-gated chloride ion channels, which are present in invertebrate nerve and muscle cells but absent in mammals. This binding causes an influx of chloride ions into the affected cells, leading to hyperpolarization of cell membranes, paralysis, and subsequent death of susceptible parasites. The remarkable selectivity of ivermectin for invertebrate-specific receptors provides an excellent margin of safety in mammalian hosts, allowing effective antiparasitic activity at doses far below those that would cause toxicity in treated animals. Ivermectin also demonstrates some activity at gamma-aminobutyric acid (GABA) receptors, which may contribute to its antiparasitic effects, particularly against arthropod ectoparasites.

Ivermectin is commercially available in numerous formulations designed to accommodate different species, management systems, and treatment preferences. Injectable formulations (typically 1% or 10 mg/mL) are administered subcutaneously in cattle and swine. Pour-on formulations (0.5% or 5 mg/mL) are applied topically along the backline of cattle and provide comparable efficacy through transcutaneous absorption. Oral formulations including pastes, drenches, and feed premixes are available for various species. The lipophilic nature of ivermectin results in accumulation in adipose tissue with slow release over time, providing extended duration of activity against reinfection—typically 2-3 weeks of persistent effect depending on the target parasite and host species.

Regulatory approval of ivermectin encompasses multiple food animal species including cattle, swine, sheep, and horses, with specific formulations and doses approved for each target species. The drug is classified as a non-prescription product in the United States for most livestock formulations, though regulations vary internationally. Extensive clinical experience over four decades has established ivermectin as a safe and effective tool for livestock parasite management when used according to label directions. However, the widespread use of ivermectin has also driven the development of resistance in multiple parasite species, necessitating careful attention to resistance management strategies in contemporary parasite control programs.

Ivermectin injectable and pour-on formulations are FDA-approved for treatment and control of a comprehensive range of gastrointestinal nematodes in cattle. Labeled indications encompass adult and immature stages of Ostertagia ostertagi (including inhibited fourth-stage larvae responsible for Type II ostertagiasis), Haemonchus placei (barber pole worm), Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, Oesophagostomum radiatum (nodular worm), Nematodirus helvetianus, Nematodirus spathiger, Bunostomum phlebotomum (hookworm), Strongyloides papillosus (threadworm), and Trichuris spp. (whipworm). This comprehensive coverage of economically important gastrointestinal parasites makes ivermectin a primary treatment option across diverse cattle production systems worldwide.

Beyond gastrointestinal nematodes, ivermectin demonstrates excellent efficacy against parasites affecting other organ systems in cattle. Lungworms (Dictyocaulus viviparus) causing parasitic bronchitis are effectively controlled, preventing the coughing, respiratory distress, and production losses associated with verminous pneumonia. Eyeworms (Thelazia spp.) residing in the conjunctival sac and associated structures are eliminated. Tissue-dwelling parasites including cattle grubs (Hypoderma bovis and H. lineatum)—the larval stages of warble flies that migrate through host tissues and emerge through the hide—are controlled when treatment is timed appropriately relative to the grub migration cycle.

The ectoparasiticide activity of ivermectin addresses several economically significant external parasites affecting cattle productivity. Labeled indications include treatment of sucking lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus) and biting lice (Bovicola bovis), parasites that cause irritation, hide damage, blood loss, and reduced production efficiency. Sarcoptic mange (Sarcoptes scabiei var. bovis) and psoroptic mange (Psoroptes ovis) mites are controlled, addressing these intensely pruritic conditions that significantly impact animal welfare. The pour-on formulation additionally provides control of horn flies (Haematobia irritans) for an extended period following application.

In swine production, ivermectin injectable is approved for treatment of gastrointestinal roundworms including Ascaris suum (adult and fourth-stage larvae), Hyostrongylus rubidus (red stomach worm), Oesophagostomum species (nodular worms), and Strongyloides ransomi (threadworm). Lungworms (Metastrongylus spp.) and kidney worms (Stephanurus dentatus) affecting the urinary system are within the ivermectin spectrum. External parasites controlled in swine include sarcoptic mange mites (Sarcoptes scabiei var. suis) and sucking lice (Haematopinus suis). The broad-spectrum activity allows comprehensive parasite control with a single treatment, simplifying management in commercial swine operations.

Sheep and goats commonly receive ivermectin for control of internal parasites, though approval status and specific indications vary by formulation and country. Key target parasites in small ruminants include Haemonchus contortus (a highly pathogenic blood-feeding parasite), Ostertagia circumcincta, Trichostrongylus species, Cooperia species, and Nematodirus species. Extra-label use is common in goats, as few products are specifically approved for caprine species; however, goats metabolize ivermectin more rapidly than sheep or cattle, often requiring higher doses and more frequent treatment. Consultation with a veterinarian regarding appropriate extra-label protocols is essential for goat producers.

The standard dose of ivermectin for cattle is 200 micrograms per kilogram of body weight (0.2 mg/kg) when administered by subcutaneous injection. Using the 1% injectable formulation (10 mg/mL), this equates to 1 mL per 50 kg (110 pounds) of body weight. The injection is administered subcutaneously, preferably in the neck region in front of the shoulder, to minimize potential carcass trim from injection site lesions. Proper injection technique—including use of appropriately sized needles (16-18 gauge, 0.5-1 inch length), single-use needles, aseptic procedures, and adherence to maximum volume per injection site—reduces the incidence of injection site reactions and ensures complete drug absorption.

For the pour-on formulation in cattle, the dose is 500 micrograms per kilogram of body weight (0.5 mg/kg), applied topically along the midline of the back from the withers to the tailhead. Using the 0.5% pour-on solution (5 mg/mL), this corresponds to 1 mL per 10 kg (22 pounds) of body weight. The higher dose relative to injectable administration compensates for the lower bioavailability of topical application. Pour-on should be applied to dry cattle, as wet hair coats or precipitation shortly after application can reduce absorption and efficacy. Animals should not have access to water bodies immediately following treatment to prevent wash-off and environmental contamination.

Swine receive ivermectin at 300 micrograms per kilogram of body weight (0.3 mg/kg) by subcutaneous injection in the neck region. Using the 1% injectable solution, this equates to 1 mL per 33 kg (approximately 75 pounds) of body weight. The higher dose in swine relative to cattle reflects species differences in drug metabolism and tissue distribution. The neck injection site is preferred to avoid lesions in valuable ham cuts. For sow herds, treatment 7-14 days before farrowing helps reduce parasite transmission to piglets through the farrowing environment.

Sheep receive ivermectin at 200 micrograms per kilogram (0.2 mg/kg) by subcutaneous injection or oral drench, depending on formulation availability. Oral drench formulations provide convenience for treating large numbers of sheep rapidly. Goats require higher doses than sheep—typically 400-600 micrograms per kilogram (0.4-0.6 mg/kg)—due to more rapid drug metabolism in caprine species. This higher goat dose usually represents extra-label use and should be conducted under veterinary guidance with appropriate extended withdrawal times established through resources such as the Food Animal Residue Avoidance Databank (FARAD).

Treatment timing should be strategically planned based on parasite epidemiology and production goals. Common treatment times in cattle include spring turnout (to reduce initial pasture contamination), mid-summer (to address peak larval availability), and fall housing (to eliminate accumulated burdens before winter). For cattle grub control, treatment should occur after heel fly activity has ceased but before grub migration to sensitive tissues—typically November through February in North America—to avoid adverse reactions from dying larvae in the esophageal or spinal regions. In swine, treatment is often coordinated with production phases such as pre-farrowing, weaning, or entry to finishing facilities.

Withdrawal times must be strictly observed for food safety. Cattle treated with ivermectin injectable require a 35-day meat withdrawal; pour-on treated cattle require 48 days. Swine have a 18-day meat withdrawal following injectable ivermectin. Ivermectin is not approved for use in female dairy cattle of breeding age, and use in lactating dairy cattle is prohibited due to the absence of an established milk withdrawal time. These withdrawal periods may vary by country and formulation, and producers should verify requirements against current product labeling before marketing animals.

Ivermectin demonstrates an excellent safety profile across approved species when administered according to label directions, consistent with the wide margin of safety characteristic of macrocyclic lactone compounds. The selectivity of ivermectin for invertebrate glutamate-gated chloride channels, which are absent in mammalian species, provides this favorable safety margin. Four decades of clinical use and post-market surveillance have confirmed that adverse effects are uncommon and generally mild at recommended doses. The established safety record has contributed to ivermectin's widespread adoption as a first-line antiparasitic agent in livestock production systems globally.

Injection site reactions represent the most commonly observed adverse effect following subcutaneous ivermectin administration. Transient swelling at the injection site may occur and can persist for several weeks before resolution. In some animals, more pronounced tissue reactions including granulomas or sterile abscesses may develop. These reactions reflect tissue response to the drug vehicle rather than the active ingredient itself. Proper injection technique—subcutaneous rather than intramuscular placement, appropriate needle selection, aseptic procedures, and adherence to recommended injection volumes per site—minimizes the incidence of injection site complications. In cattle destined for slaughter, injection site lesions may require carcass trimming, representing an economic concern addressed by the withdrawal period requirements.

Neurological signs including ataxia, depression, mydriasis (dilated pupils), and hypersalivation have been reported following ivermectin administration, typically in association with accidental overdose, administration to very young animals, or use in species or breeds with increased sensitivity. The blood-brain barrier normally excludes macrocyclic lactones from the central nervous system, but this protective barrier may be incomplete in neonates or compromised in certain conditions. When neurological signs occur, they may persist for several days to weeks depending on severity of exposure. Supportive care is indicated, as no specific antidote exists for macrocyclic lactone toxicity. Most affected animals recover fully with appropriate supportive management.

Host-parasite reactions can occur when ivermectin treatment kills large numbers of parasites in heavily infected animals or parasites dwelling in sensitive anatomical locations. In cattle treated for cattle grubs during the migration period, dying larvae in the esophageal region can cause local swelling leading to bloat, while those near the spinal column can cause hindquarter weakness, ataxia, or paralysis. These reactions are inflammatory responses to dying parasites rather than direct drug toxicity. Risk is minimized by treating during the recommended treatment window (November-February in most of North America) when grubs have not yet reached critical anatomical sites. If treatment during migration is unavoidable, treating smaller groups allows closer monitoring and prompt intervention if complications arise.

Species-specific sensitivities warrant attention when ivermectin is used outside cattle and swine production. Certain dog breeds—particularly Collies, Australian Shepherds, and related herding breeds—carry ABCB1 (MDR1) gene mutations that dramatically increase susceptibility to ivermectin toxicity due to impaired blood-brain barrier function. While this is primarily a canine concern, farm dogs may be exposed through licking pour-on residue from treated cattle, consuming manure from treated animals, or accidental access to drug containers. Dogs with suspected ABCB1 mutations should be kept away from treated livestock and ivermectin storage areas. Horses are generally tolerant of ivermectin at equine doses but are more sensitive than cattle or swine.

Ivermectin is contraindicated for use in female dairy cattle of breeding age, as no milk discard time has been established for cattle formulations. This restriction applies regardless of lactation status—non-lactating dairy heifers and dry cows are also excluded. The regulatory prohibition reflects food safety requirements regarding drug residues in milk rather than evidence of harm from milk containing ivermectin residues. Dairy producers requiring parasite control in replacement heifers or dry cows must select alternative products with established milk withdrawal times, such as eprinomectin pour-on, or use ivermectin only in animals that will never enter the dairy string.

Ivermectin should not be administered to calves intended for veal production when withdrawal time constraints cannot be accommodated. The relatively young slaughter age of veal calves combined with the 35-48 day withdrawal times for cattle ivermectin formulations creates challenges for treatment timing. Veal producers requiring parasite control should select products specifically approved for their production timeline or ensure adequate time between treatment and marketing. Consultation with a veterinarian can help identify appropriate treatment options compatible with veal production schedules.

Animals with known hypersensitivity to avermectin compounds should not receive ivermectin treatment. While true allergic reactions are rare, animals that have demonstrated adverse reactions to ivermectin, doramectin, eprinomectin, moxidectin, or related macrocyclic lactones should be excluded from further treatment with any drug in this class. Cross-reactivity among macrocyclic lactones has been documented, and previous adverse reactions should prompt selection of anthelmintics from alternative chemical classes such as benzimidazoles or imidazothiazoles.

Use of ivermectin in severely debilitated, stressed, or diseased animals requires careful evaluation of the risk-benefit ratio. While not an absolute contraindication, compromised animals may have altered drug distribution or metabolism that affects safety margins. In animals with heavy parasite burdens, the death of large numbers of parasites may provoke inflammatory responses that could exacerbate the animal's condition. Providing supportive care to stabilize compromised animals before antiparasitic treatment, or implementing treatment approaches that result in more gradual parasite elimination, may be appropriate strategies. Treatment decisions for significantly compromised animals should involve veterinary consultation to assess individual circumstances and recommend appropriate therapy.

The most clinically significant drug interaction involving ivermectin is concurrent administration with other macrocyclic lactone anthelmintics. Combining ivermectin with doramectin, eprinomectin, moxidectin, or other avermectin/milbemycin class drugs can result in additive toxicity, potentially exceeding safe exposure levels and increasing the risk of adverse effects. This interaction is relevant when animals are moved between properties with different deworming programs, when combination products are used without recognizing all active ingredients, or when multiple products are administered through error. A thorough treatment history should be obtained before administering ivermectin, and adequate time should elapse between treatments with different macrocyclic lactones based on the duration of activity of each product.

Ionophore antibiotics used in cattle production interact with macrocyclic lactones through effects on P-glycoprotein transport mechanisms. Ionophores including monensin (Rumensin), lasalocid (Bovatec), and similar compounds are commonly incorporated in cattle feeds for growth promotion and coccidiosis prevention. P-glycoprotein functions as an efflux pump that normally limits macrocyclic lactone penetration into the central nervous system. Ionophore-mediated interference with P-glycoprotein could theoretically increase ivermectin CNS penetration and the risk of neurological toxicity. While clinical problems are uncommon at labeled doses of both drug classes, concurrent use warrants awareness, and cattle should be monitored following ivermectin treatment when receiving ionophore-containing feeds.

Other P-glycoprotein inhibitors beyond ionophores may affect ivermectin disposition, though specific interactions in livestock have not been extensively characterized. Drugs recognized as P-glycoprotein inhibitors include ketoconazole, itraconazole, quinidine, verapamil, and cyclosporine. While these specific drug combinations are uncommon in routine livestock practice, they may be relevant in intensive care situations involving valuable breeding stock receiving multiple medications. When ivermectin treatment is planned for animals receiving other medications, review of potential interactions and veterinary consultation is advisable.

Vaccination timing relative to ivermectin administration has been studied without evidence of significant interference with immune responses. However, as a precaution, some practitioners recommend separating antiparasitic treatment from vaccination by 48-72 hours when logistically feasible, particularly for modified-live virus vaccines. When concurrent processing is necessary for management efficiency—such as during handling of cattle that will not be gathered again soon—the benefits of comprehensive health management generally outweigh theoretical interaction concerns, and both ivermectin administration and vaccination may proceed concurrently. Killed vaccines and toxoids are generally considered less susceptible to potential interference from concurrent drug administration.

Human safety precautions during ivermectin handling and administration minimize occupational exposure risk to farm personnel. Pour-on formulations are designed to enhance drug penetration through skin, making human dermal contact a relevant exposure concern. Waterproof gloves should be worn during handling and application of all ivermectin formulations. Direct skin contact should be avoided; if contact occurs, the affected area should be washed promptly with soap and water. Eye protection is recommended during use, as ocular exposure to formulation vehicles can cause irritation. If eye contact occurs, eyes should be flushed thoroughly with clean water and medical attention sought if irritation persists. Personnel with known sensitivity to avermectin compounds should avoid handling ivermectin products. Injectable formulations pose needlestick hazards requiring standard sharps precautions.

Food safety and residue avoidance require strict adherence to established withdrawal times before slaughter. Cattle treated with ivermectin injectable must observe a 35-day meat withdrawal; pour-on treated cattle require 48 days. Swine require 18 days following injectable ivermectin. Sheep withdrawal times vary by formulation and should be verified against current product labeling. Treated animals should be clearly identified to prevent inadvertent premature slaughter. Treatment records documenting dates, products, doses, animal identification, and calculated withdrawal dates should be maintained as part of quality assurance programs. Extra-label use in any species requires consultation with FARAD or a veterinarian to establish appropriate extended withdrawal times.

Environmental considerations apply to ivermectin use given its broad-spectrum toxicity to non-target invertebrates. Ivermectin residues excreted in feces of treated animals can affect dung beetle populations and other coprophagous invertebrates that play important ecological roles in pasture systems. Pour-on formulations may pose additional environmental risk through run-off into water bodies, where aquatic invertebrates and fish are particularly sensitive to macrocyclic lactone toxicity. Treatment should be avoided immediately before heavy rainfall, and recently treated cattle should not have direct access to streams, ponds, or sensitive waterways. Strategic, targeted treatment approaches reduce environmental drug loading while maintaining effective parasite control.

Anthelmintic resistance to ivermectin has been documented in multiple nematode species affecting cattle, sheep, goats, and horses worldwide, representing a critical threat to the continued utility of this drug class. Resistance development has been driven by decades of intensive use, often with practices that enhance selection pressure including underdosing, treating all animals prophylactically regardless of parasite burden, and exclusive reliance on macrocyclic lactones without class rotation. Practices supporting resistance management include accurate dosing based on actual body weights, maintenance of refugia through selective treatment strategies, rotation among anthelmintic classes with different mechanisms of action, and monitoring treatment efficacy through fecal egg count reduction tests. When reduced efficacy is suspected, consultation with a veterinarian or parasitologist can guide program adjustments.

Proper use documentation supports both regulatory compliance and resistance management objectives. Records should include treatment date, animal identification (individual or group), product name and manufacturer, lot or serial number, dosage administered, route of administration, withdrawal date, and identity of the person administering treatment. These records enable traceback capability, demonstrate quality assurance program compliance, and provide essential data for monitoring treatment efficacy and making evidence-based parasite control decisions. Electronic record-keeping systems integrated with other herd management functions improve record accuracy and accessibility for analysis.

Ivermectin products should be stored according to label specifications to maintain product stability and efficacy throughout the shelf life. Injectable and pour-on formulations should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from direct sunlight and extreme temperature fluctuations. Exposure to elevated temperatures can accelerate drug degradation, while freezing may cause precipitation or phase separation. Products should be stored in climate-controlled areas rather than uninsulated barns, vehicles, or storage buildings subject to temperature extremes. Oral formulations may have specific storage requirements; label directions should be followed precisely. Verification of storage temperature through thermometer monitoring supports product quality assurance.

Multi-dose container handling significantly impacts product quality and animal health outcomes. When using multi-dose injectable vials, appropriate aseptic technique prevents contamination. The rubber stopper should be cleaned with alcohol or disinfectant before each needle entry. Needles should be changed frequently rather than using a single needle for multiple stopper penetrations, as repeated use dulls needles and can introduce contaminants. Multi-dose vials should be used within the timeframe specified on the label once opened. Recording the date of first opening on containers supports appropriate use timelines. Pour-on formulations used through calibrated applicator equipment should have application systems cleaned and maintained according to manufacturer recommendations to ensure accurate dosing.

Disposal of ivermectin products, empty containers, and application equipment must comply with applicable environmental regulations. Ivermectin is toxic to fish and aquatic invertebrates at very low concentrations, and improper disposal can cause significant environmental harm. Empty containers should be triple-rinsed before disposal, with rinsate applied to land areas away from water sources, drainage systems, and wells. Containers should be rendered non-reusable by puncturing or crushing. Used needles and syringes should be placed in designated sharps containers and disposed of through appropriate medical waste channels. Unused or expired product should be disposed of through veterinary pharmaceutical return programs, agricultural chemical collection events, or hazardous waste facilities. Product should never be disposed of by emptying into drains, water bodies, or areas where groundwater contamination could occur.

Cattle breed considerations for ivermectin primarily relate to production type (dairy versus beef) rather than breed-specific drug sensitivity. Dairy breeds—Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and others managed for milk production—are subject to specific use restrictions prohibiting ivermectin in female cattle of breeding age due to the absence of established milk withdrawal times. This restriction applies regardless of lactation status. Dairy steers being raised for beef production are not subject to dairy restrictions and may receive ivermectin according to beef cattle label directions with appropriate meat withdrawal time observance. Dairy producers requiring antiparasitic treatment in animals that will eventually join the milking herd should consider alternatives such as eprinomectin with its established zero milk withdrawal.

Beef cattle across all breeds may receive ivermectin according to label directions without breed-specific restrictions. Body condition differences among breeds and individuals may influence drug pharmacokinetics; heavily conditioned animals with significant fat cover may demonstrate prolonged tissue residence of lipophilic ivermectin, while lean animals may experience more rapid clearance. While labeled withdrawal times incorporate appropriate safety margins across the expected range of animal conditions, awareness of these factors supports informed management decisions for animals that may be marketed near the end of withdrawal periods. All cattle should be accurately weighed or weight-estimated using appropriate methods to ensure correct dosing.

Small ruminant species present important considerations for ivermectin use. Sheep generally tolerate ivermectin well at approved doses and may receive approved formulations according to label directions. Goats, however, metabolize ivermectin and other macrocyclic lactones more rapidly than sheep or cattle, resulting in lower plasma concentrations and reduced efficacy at standard doses. Extra-label use of higher doses (typically 400-600 mcg/kg orally or 300 mcg/kg subcutaneously) is common practice in goat production but requires veterinary guidance for establishing appropriate protocols and extended withdrawal times. This species difference is metabolic rather than true drug sensitivity and reflects the need for dose adjustment rather than avoidance.

Swine breeds may receive ivermectin according to label directions without documented breed-specific restrictions. Production stage considerations—such as pre-farrowing treatment of sows to reduce parasite transmission to piglets—apply across all breeds. Individual animal sensitivity can vary, and any animal demonstrating adverse reactions should be identified and excluded from future macrocyclic lactone treatment. Young pigs with incompletely developed blood-brain barriers warrant careful attention to accurate dosing and post-treatment monitoring. The consistent efficacy of ivermectin across swine breeds when properly dosed has supported its widespread adoption in commercial swine production for controlling internal and external parasites.

Within the macrocyclic lactone class, several alternative compounds offer similar broad-spectrum activity with characteristics that may favor their selection in specific situations. Doramectin (Dectomax) provides comparable spectrum and similar formulation options (injectable and pour-on) with slightly longer duration of activity against some parasites. Eprinomectin (Eprinex) is the preferred macrocyclic lactone for dairy cattle due to its zero milk withdrawal pour-on formulation. Moxidectin (Cydectin) is a milbemycin derivative with extended duration of activity and potential advantages against some ivermectin-resistant parasite populations, making it valuable for resistance management strategies. Selection among macrocyclic lactones depends on target species, production class, resistance patterns on the individual operation, and specific management requirements.

Anthelmintics from different chemical classes provide essential options for resistance management and may be preferred when macrocyclic lactone resistance is suspected or confirmed. Benzimidazoles including fenbendazole (Safe-Guard, Panacur) and albendazole (Valbazen) act through inhibition of microtubule formation, a mechanism distinct from macrocyclic lactones. These drugs offer broad-spectrum nematode control and are available in multiple formulations. Levamisole (Prohibit, Levasole) represents the imidazothiazole class and acts through nicotinic acetylcholine receptor agonism. Class rotation among macrocyclic lactones, benzimidazoles, and imidazothiazoles forms the foundation of resistance management programs designed to preserve drug efficacy.

Combination products incorporate ivermectin with other active ingredients to address broader parasite spectrum or specific concurrent infections. Ivermectin/clorsulon combinations (Ivomec Plus) provide concurrent activity against liver flukes—parasites not affected by ivermectin alone—along with the standard nematode and arthropod spectrum. Combinations of macrocyclic lactones with benzimidazoles are available in some markets, providing complementary mechanisms of action that may address mixed parasite populations including resistant strains. When selecting combination products, careful attention to the spectrum, withdrawal times for all active components, and approved uses ensures appropriate application. The choice between combination products and sequential single-agent treatments depends on specific parasite challenges, economic considerations, and handling logistics of individual operations.